Pharmacy Law Blog

MARCH 13, 2018

The relator McKenzie Stepe, a former RS sales representative, originally filed her complaint in December 2013. The Health Law Firm represents pharmacists and pharmacies in DEA, DOH and FDA investigations, qui tam and whistleblower cases, regulatory matters, licensing issues, litigation, administrative hearings, inspections and audits.

Fraud 52

Fraud Governance Licensing FDA 52

Verisys

NOVEMBER 14, 2023

Primary source verification must be done to confirm a provider’s education, professional license and certifications, medical training, work history, references, and more. Provider information should be continuously monitored for any changes to exclusion or license status. However, verifying a provider’s credentials is essential.

Licensing 52

Licensing Medicaid Medicaid Governance 52

Verisys

JANUARY 18, 2022

Primary source verification must be done to confirm a provider’s education, professional license and certifications, medical training, work history, references, and more. Provider information should be continuously monitored for any changes to exclusion or license status. Food and Drug Administration (FDA). Treasury Department.

Licensing 52

Licensing Medicaid Medicaid Governance 52

Kaiser Health News

MARCH 15, 2023

But she said nothing worked as well as methadone, an opioid she has taken since 2013. The FDA approves new drugs and their reformulations, but the guidance it provides for how to start or wean patients could urge clinicians to do so with caution, Kertesz said. She hopes her current doctor won’t do the same.

Doctors 52

Doctors Prescription Drug Pricing FDA COVID-19 52

SQA

JUNE 10, 2021

The CDSCO has postponed deadlines for regulating implantable devices and other medical products for which manufacturers or importers have already applied for licenses under the Medical Device Rules 2017. FDA plant inspection and pay $50 million in fines and forfeiture. Guidance on the Licensing of Biosimilar Products, 06 May 2021.

COVID-19 52

COVID-19 FDA COVID-19 Vaccine Compliance 52

HIT Consultant

SEPTEMBER 27, 2023

Industry leaders, IEEE SA members, and the FDA are all working together to create accuracy standards for this innovative technology. Once cleared by the FDA, these medical devices will be Class 2 software as medical device technology. License: Creative Commons attribution CC BY 3.0 DOI: 10.1097/MBP.0000000000000467

US Department of Health and Human Services 116

US Department of Health and Human Services FDA Licensing 116

Drug & Device Law

DECEMBER 29, 2023

Since the FDA requires pre-approval of any warnings about off-label uses, preemption at some point should have been pre-ordained under the Mensing ( 2011+1 ) independence principle, but off-label use did not really figure in Zofran ’s analysis. The FDA’s five reviews of teratogenic risk all came to the same conclusion.

FDA 105

FDA US Department of Health and Human Services COVID-19 COVID-19 Vaccine 105

Drug & Device Law

FEBRUARY 2, 2023

2013); Massa v. Texas, unlike most states, enforces a strong statutory presumption that prescription medical product warnings complying with FDA requirements imposed by “pre-market approval or licensing of the product” are adequate as a matter of law. Novartis Pharmaceuticals Corp. , 2d 898, 909-10 (W.D. Genentech Inc.

FDA 59

FDA Licensing Fraud 59

Drug & Device Law

OCTOBER 27, 2022

640.65, an FDA biologics regulation that requires entities that collect blood via a particular method to establish “donor identification system[s]” that “positively identifies each donor and relates such donor directly to his blood and its components as well as to his accumulated records and laboratory data.”. 2013); Heisner v.

FDA 59

FDA Licensing Compliance 59

Drug & Device Law

JUNE 2, 2022

2012), addressed a challenge to the application of Idaho’s Pain-Capable Unborn Child Protection Act to criminalize the use of an FDA-approved abortifacient medication obtained through an internet prescription and mailed to the plaintiff from out of state. As we discussed here , McCormack v. Hiedeman, 694 F.3d 3d 1004 (9th Cir. Abbott , 951 F.

FDA 127

FDA Licensing 127

Drug & Device Law

MARCH 7, 2022

These allegations lack any contention or inference that [defendant] withheld or misrepresented information to the FDA. . ., Francis , 2013 WL 5603848, at *2 (D.N.J. It does not give him license to evade the less rigid ? 2013 WL 5603848, at *2 (citing Malleus v. the threshold for permitting punitive damages. 2, 2020). “In

Fraud 59

Fraud FDA Licensing Pharmaceutical Industry 59